RGCC (circulating tumor cells)

Liquid biopsy testing built around circulating tumor cells to guide treatment and monitor disease.

Vetted listing

Testing

Consented intake · your records travel with you · nothing moves without your sign-off

Why RGCC exists

RGCC analyzes blood and other bodily fluids for biomarkers, with a focus on circulating tumor cells. The testing is designed to gather distinctive markers that can guide treatment and monitor disease progression, including minimum residual disease monitoring and early detection. It gives patients another window into how their cancer is behaving over time.

Around 3 weeks following a blood drawCLIA · 99D2283882CAP · 9239089IAS accredited · Testing Laboratory TL-836 and Medical Laboratory ML-103Founded in 2004 by Dr. Ioannis Papasotiriou

1
Simple blood draw
Testing starts with a blood sample drawn from the patient.
2
Analysis of circulating tumor cells
The laboratory analyzes circulating tumor cells and associated cancer markers in the bloodstream to reveal the genetic composition of the cancer.
3
Summary report
An extensive summary is provided around 3 weeks after the blood draw to support personalized treatment decisions.

Prefer the source? RGCC (circulating tumor cells)'s own site has more.

Share your records

We'll pre-fill the intake from your records — no retyping.

Start sharing →

Check your coverage

See if your insurance covers this and estimate out-of-pocket cost.

Check coverage →

Coverage, insurance & cost

The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how RGCC (circulating tumor cells) handles billing.

We don't have confirmed insurance details for RGCC (circulating tumor cells) yet. Start a coverage check with your plan, or contact the provider directly.

Common questions about RGCC

How does RGCC work?

1. Simple blood draw — Testing starts with a blood sample drawn from the patient. 2. Analysis of circulating tumor cells — The laboratory analyzes circulating tumor cells and associated cancer markers in the bloodstream to reveal the genetic composition of the cancer. 3. Summary report — An extensive summary is provided around 3 weeks after the blood draw to support personalized treatment decisions.

How long does RGCC take?

Around 3 weeks following a blood draw

How do I connect with RGCC?

Through OpenCancer's consented intake: enter your details once, choose exactly which records travel with the request, and sign a consent that covers this connection only. Nothing is shared without your sign-off.

Understand this before you decide

Patient Information

Guide from RGCC (circulating tumor cells)

FAQ

Guide from RGCC (circulating tumor cells)

Ask about this service

Answers grounded in RGCC's details here. Educational only; your oncologist directs treatment.

Ask OpenCancer · answers grounded in this storefront

Also consider

Other providers in similar categories.

BostonGene

6 offerings

Gather distinctive biomarkers that can guide treatment and monitor disease progression

Foundation Medicine

6 offerings

FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.